USPTO serial 50018558
OPTIKINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- —
What this means
Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.
Need help with OPTIKINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Junction City, KS, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dianne M. Smith-Misemer
Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 Mastin St., Suite 1000Overland Park, KS 66210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Recombinant cytokine proteins in raw material form for scientific and medical research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific and research use; Non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for scientific, laboratory and medical research | ACTIVE | — |
| 005 | Chemicals, namely, non-animal derived cell culture media for promoting cell growth, optimization, and productivity, for medical or veterinary purposes; Recombinant cytokine proteins for use as cell growth media for growing cells for clinical use; Recombinant cytokine proteins for use as reagents for clinical medical purposes; Recombinant cytokine protein arrays for clinical medical diagnosis purposes; Recombinant cytokine proteins sold as a component ingredient of therapeutic pharmaceuticals for the treatment of immune system related diseases and disorders; Recombinant cytokine proteins for use as reagents for medical use, for the optimization of in vitro expansion of cells; Pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 28, 2026 | NWAP | NEW APPLICATION ENTERED | — |